IBR854 shows no dose-limiting toxicity in 19-patient NK cell trial for tumors
The first-in-human, open-label study of a 5T4-targeted allogeneic NK cell therapy reported a 43.8% disease control rate but only 43 days of median progression-free survival, leaving durability unresolved.
Executive Summary
- IBR854, a 5T4-targeted allogeneic NK cell therapy, produced no dose-limiting toxicities across 19 patients in five dose cohorts, meeting the trial's safety-primary endpoints and clearing the bar the phase 1 design was built to test Press ReleasePress ReleaseJul 6, 2026.
- A 43.8% disease control rate came with a median progression-free survival of only 43 days, a short duration that limits how much the result says about durable antitumor activity in this heavily pretreated, 4L+ population Press ReleasePress ReleaseJul 6, 2026.
- Going into the trial, AppliedXL's endpoint-met probability sat at 2.4%, a figure driven mainly by operational features like enrollment per arm and country count rather than by mechanism-specific evidence [AXL-MODEL].
- No direct precedent for a 5T4-targeted allogeneic NK therapy exists; the nearest comparators are 5T4 T-cell engagers and CAR-T programs still in phase 1, none of which share the NK-cell modality.
- The safety data support further development of the platform, but the short progression-free survival and small single-country cohort mean this readout is hypothesis-generating, not decision-grade, for an efficacy claim.
The result
The trial enrolled 19 patients with unresectable, locally advanced or metastatic tumors who had exhausted standard therapy, testing IBR854 across five dose cohorts from 3.0x10^9 to 12.0x10^9 cells per dose in a 3+3 escalation design Press ReleasePress ReleaseJul 6, 2026. No dose-limiting toxicities occurred, and no anti-drug antibodies were detected against the antibody-coupled NK cells Press ReleasePress ReleaseJul 6, 2026. The most common treatment-emergent adverse events were elevated interleukin levels in 42.1% of patients, infusion-related reactions in 31.6%, and fever in 21.1% Press ReleasePress ReleaseJul 6, 2026. The trial's two registered primary endpoints, DLT incidence through day 21 and adverse-event incidence and severity through day 90, are both safety measures rather than efficacy measures NCT06001684Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid TumorsNCT06001684.
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What it does not establish
The abstract reports a disease control rate of 43.8% and a median progression-free survival of 43 days, disclosed as secondary endpoints under the trial's registered design Press Release+1Press ReleaseJul 6, 2026Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid TumorsNCT06001684. The abstract states the drug "demonstrated an acceptable safety and tolerability profile and achieved disease stabilization in a subset of heavily pretreated patients," and that "these findings support further clinical development of 5T4-targeted antibody-coupled allogeneic NK cell therapy" Press ReleasePress ReleaseJul 6, 2026. A 43-day median progression-free survival in a 19-patient, single-arm, open-label cohort with no control group is a short window; it cannot establish durable clinical benefit, and the abstract discloses no p-values or confidence intervals around either efficacy figure Press ReleasePress ReleaseJul 6, 2026.
Model context
Ahead of this readout, AppliedXL's model placed the endpoint-met probability at 2.4% and completion probability at 66.5% [AXL-MODEL]. The clinical-significance driver mix leaned heavily on operational-design features, enrollment per arm carried the largest negative weight, alongside country count and endpoint measurement window, domains that reflect trial structure rather than the biology of 5T4-targeted NK cell engineering [AXL-MODEL]. Because a safety-primary phase 1 trial with n=19 is not built to resolve efficacy, that 2.4% figure should be read as a low base-rate expectation shaped by trial size and design, not as a specific rejection of the mechanism.
Competitive landscape
No approved or late-stage precedent exists for a 5T4-targeted allogeneic NK cell therapy. The closest active comparators target the same antigen with different modalities: FTL008.16 from Sound Biopharmaceuticals and ACR246 from Hangzhou Adcoris Biopharmacy are both phase 1, and CBA-1535 from Chiome Bioscience is a 5T4/CD3 T-cell engager, also in phase 1. Field activity in the 5T4 target itself has declined, with 42 recent trials against 399 older ones, a ratio the dossier's landscape data flags as a steep drop-off. Only five sponsors have ever run a 5T4-times--tumor trial, and none has failed to date, giving the target a thin but so-far unblemished track record.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.